Articles tagged "Liver transplantation"

2017 American Transplant Congress
Liver Transplantation for Babies Weighing Less Than 10 kg.
A. Akdur,¹ G. Moray,¹ F. Ozcay,² A. Torgay,³ M. Haberal.¹
¹General Surgery and Transplantation, Baskent University, Ankara, Turkey; ²Pediatric Gastroenterology, Baskent University, Ankara, Turkey; ³Anesthesiology, Baskent University, Ankara, Turkey
Introduction: Liver transplantation (LT) is an established therapy for children with end-stage liver disease or liver failure. LT in small babies remains challenging due to…
2017 American Transplant Congress
Burden of Early Hospitalization Among Liver Transplant Recipients.
P. Sharma,¹ N. Goodrich,³ D. Schaubel,² A. Smith,³ R. Merion.^3,4
¹Gastroenterology, University of Michigan, Ann Arbor, MI; ²Biostatistics, University of Michigan, Ann Arbor, MI; ³Arbor Research Collaborative for Health, Ann Arbor, MI; ⁴Surgery, University of Michigan, Ann Arbor, MI
Hospitalization is known to occur frequently in the first six months following liver transplantation (LT). We examined the burden of hospitalization within 6 months of…
2017 American Transplant Congress
Multidisciplinary Psychosocial Liver Transplant Evaluation in Patients with Alcoholic Liver Disease – Moving Beyond the Six-Month Rule.
K. Wenzke,¹ S. Kelly,² J. Eickhoff,³ M. Lucey,¹ J. Rice.¹
¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI; ²Department of Medicine, The Ohio State University, Columbus, OH; ³Department of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI
Background: For patients with alcoholic liver disease (ALD), many transplant programs and payers have a mandatory six-month sobriety interval prior to transplant eligibility. However, the…
2017 American Transplant Congress
Long-Term Preservation of Renal Function in Liver Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Delayed Initiation of Calcineurin Inhibitors.
I. Bajjoka, A. Yaldo, C. Crombez, K. Brown, M. Abouljoud.
Transplant Institute, Henry Ford Health System, Detroit, MI
Methods: A single-center retrospective analysis of medical records of 989 liver transplant recipients from 2001-2010 were reviewed and evaluated for patients who received thymo induction…
2017 American Transplant Congress
Plasma Cell Hepatitis in Primary Sclerosing Cholangitis Patients: 15-Year Experience at a Transplant Center.
J. Putra,¹ T. Schiano,² M. Fiel.³
¹Pathology, Icahn School of Medicine at Mount Sinai, New York, NY; ²Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY
Background: Plasma cell hepatitis (PCH) is an uncommon liver graft dysfunction which occurs in liver transplant (LT) recipients of different etiologies other than autoimmune hepatitis.…
2017 American Transplant Congress
Share35: Increasing Biliary Complications and Healthcare Resources?
J. Fleming,¹ C. Perez,¹ M. Sobhanian,¹ D. Taber,² G. Chedister,² D. Axelrod,³ K. Chavin.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC; ³Surgery, East Carolina University, Greenville, NC
Data has shown that major outcomes of liver transplant post-Share35 have been equivalent to pre-Share35, despite organs accumulating longer CIT and traveling further.The PURPOSE of…
2017 American Transplant Congress
Cardiovascular Events Are a Substantial and Increasing Cause of Graft Loss in Liver Transplant Recipients.
M. Sell, A. Mardis, I. Lee, B. O'Brien, C. Perez, A. Rogers, C. Mardis, N. Patel, J. Fleming, H. Meadows, N. Pilch, K. Chavin, D. Taber.
Pharmacy, Transplant, MUSC, Charleston, SC
Purpose: The overall 1- and 3- year graft survival rates following liver transplant are 89.1% and 79.9%, respectively. While these numbers have vastly improved, they…
2017 American Transplant Congress
Evaluation of the Enhanced Recovery After Surgery Protocol in Living Liver Donors.
A. Khalil, S. Ganesh, C. Hughes, A. Tevar, J. Hatche, S. Esper, A. Humar.
Abdominal Transplant, UPMC, Pittsburgh, PA; Department of Surgery, Ain Shams University, Cairo, Egypt
Background: Enhanced recovery after surgery protocol has proven its efficacy in many surgery fields in controlling pain and promoting early recovery . The implication of…
2017 American Transplant Congress
Long-Term Outcomes After Liver Transplantation (tx) with Everolimus (EVR) and Mycophenolic Acid (MPA) in a Calcineurin Inhibitor-Free Regimen: The CERTITUDE Trial.
F. Saliba,¹ C. Duvoux,² S. Dharancy,³ J. Dumortier,⁴ Y. Calmus,⁵ F. Di Giambattista,⁶ F. Conti.⁵
¹AP-HP Hôpital Paul Brousse, Villejuif, France; ²AP-HP Hôpital Henri Mondor, Créteil, France; ³CHRU de Lille, Lille, France; ⁴Hôpital Edouard Herriot, Lyon, France; ⁵AP-HP Hôpital Pitié Salpêtrière, Paris, France; ⁶Novartis Pharma SAS, Rueil-Malmaison, France
Background. Long-term outcomes under EVR with MPA and no calcineurin inhibitor are undocumented after liver tx.Methods. CERTITUDE is a prospective, multicenter, observational study of liver…
2017 American Transplant Congress
Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant.
T. Sandow,¹ H. Bohorquez,² D. Kirsch,¹ A. Albar,¹ P. Thevenot,³ K. Nunez,³ D. DeVun,¹ J. Gimenez,¹ G. Galliano,⁴ A. Cohen,² G. Loss,² D. Kay,¹ P. Gulotta.¹
¹Radiology, Ochsner Clinic Foundation, New Orleans, LA; ²Transplant Surgery, Ochsner Clinic Foundation, New Orleans, LA; ³Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA; ⁴Pathology, Ochsner Clinic Foundation, New Orleans, LA
Purpose:Immune factors are pivotal against disease progression after transplant in hepatocellular carcinoma (HCC). With chemoembolization (TACE) as a bridge to liver transplant, this study compares…